Resources Archive | HUB Organoids

immunooncology

Organoid co-cultures with autologous T cells to assess toxicity and efficacy of bispecific antibodies

immunooncology

Autologous organoids and T cell co-cultures as a powerful personalized platform for immunotherapy

inflammatory bowel disease

Patient-derived organoids as a relevant tool for preclinical IBD research and drug development

immunooncology

Autologous organoids and T cell co-cultures as a powerful personalized platform for immunotherapy

oncology

Developing a patient-derived bladder cancer organoid biobank suitable for large-scale drug screenings

oncology

Development of a medium-to-high throughput organoid and bacteria co-culture platform for the assessment of host-pathogen interaction

oncology

Patient-derived organoids predict clinical response: a patient in the lab

toxicology

Human liver patient-derived HUB Organoids as a promising tool to study drug-induced liver injury and drug metabolism for improved preclinical toxicology assessment

oncology

Drug discovery to clinical trials in five years

immunooncology

De-risk your immuno-oncology drug development with HUB Organoids®

immunooncology

Application of HUB Organoids in immuno-oncology drug development

toxicology

HUB Toxicology Organoid Models

cystic fibrosis

Patient-derived organoids as a model for treatment diagnosis in Cystic Fibrosis – combinatory treatment with read-through agent, correctors and potentiator on rare mutations

organoid technology

License HUB Organoid Technology

oncology

Patient in the lab: predicting clinical responses using patient-derived organoid screening

oncology

Patient-derived organoids predict clinical response: a patient in the lab

immunooncology

Application of HUB Organoids® to Immunotherapy development

biobank

HUB Organoid Biobank

infectious disease

Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

eLife | July 2021

cystic fibrosis

Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids

J Cyst Fibros | May 2021

inflammatory bowel disease

Organoid-Derived Epithelial Monolayer: A Clinically Relevant In Vitro Model for Intestinal

J Vis Exp | July 2021

toxicology

HUB Organoids applications to drug safety and ADME evaluation

toxicology

Potential of liver organoids in preclinical evaluation of toxicity, safety and mode of action

cystic fibrosis

HUB Organoids in cystic fibrosis

organoid screening

Patient in the lab®: downscaling patient-derived organoid screening

René Overmeer, Head of Assay Development and Automation HUB Organoids

organoid screening

Model human disease and identify predictive biomarkers of response

Robert Vries, CEO HUB Organoids

organoid screening

Understanding mechanism of disease and identifying therapeutic interventions with HUB Organoids

Robert Vries, CEO HUB Organoids

inflammatory disease

Modelling human inflammation “in a dish”

Sylvia Boj, CSO HUB Organoids

oncology

Accelerating oncology drug discovery with HUB Organoids®

oncology

Tumor organoids

personalised medicine

HUB Organoids as unique tools for personalized medicine

Robert Vries, CEO HUB Organoids

infectious disease

HUB Organoids as models for precision medicine, in vitro diagnostics, and infectious disease

Robert Vries, CEO & Sylvia Boj, CSO HUB Organoids; Ryan Conder, STEMCELL Technologies

oncology

Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients

Cell | May 2015

organoid technology

Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche

Nature | May 2009

organoid technology

Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium

Gastroenterology | Nov 2011

oncology

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

eLife | Nov 2016

oncology

A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity

Cell | Jan 2018

oncology

Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids

Nat Protoc | April 2021

cystic fibrosis

G970R-CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect

Clin Transl Sci | March 2021

cystic fibrosis

Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation

J Cyst Fibros | Sep 2021 | Clinical trial

cystic fibrosis

Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis

Cell Rep | February 2019

oncology

Sequential cancer mutations in cultured human intestinal stem cells

Nature | May 2015

oncology

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors

Nat Cancer | April 2022

inflammatory bowel disease

Molecular and Functional Characterization of Human Intestinal Organoids and Monolayers for Modeling Epithelial Barrier

Inflamm Bowel Dis | Nov 2022

oncology

Long-term expanding human airway organoids for disease modeling

EMBO J | February 2019

oncology

Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

NPJ Precis Oncol | April 2021

oncology

Organoid Models of Human and Mouse Ductal Pancreatic Cancer

Cell | January 2015

oncology

Pancreatic cancer organoids recapitulate disease and allow personalized drug screening

Proc Natl Acad Sci USA | December 2019

oncology

Establishment of Pancreatic Organoids from Normal Tissue and Tumors

STAR Protocols, Cell | December 2020

organoid technology

Tissue-specific mutation accumulation in human adult stem cells during life

Nature | October 2016

organoid technology

Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver

Cell | January 2015

Resources

Have any questions?